stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) Return on invested capital
Maravai LifeSciences Holdings, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −13.6%, up 14.5 percentage points from fiscal 2025 (−28.2%). Over the past ten years it has ranged from −28.2% (fiscal 2025) to 66.1% (fiscal 2021) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −28.2% | (2.85) |
| FY2024 | −25.3% | (22.74) |
| FY2023 | −2.57% | (47.40) |
| FY2022 | 44.8% | (21.24) |
| FY2021 | 66.1% | 51.36 |
| FY2020 | 14.7% | 11.77 |
| FY2019 | 2.94% | 0.74 |
| FY2018 | 2.20% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 30.5% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| SRPT Sarepta Therapeutics, Inc. compare | −2.03% |
| MRVI Maravai LifeSciences Holdings, Inc. | −13.6% |
| VIR Vir Biotechnology, Inc. compare | −30.3% |
| MAZE Maze Therapeutics, Inc. compare | −112.4% |
| REPL Replimune Group, Inc. compare | −928.3% |
| TRVI Trevi Therapeutics, Inc. compare | −1,412.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)